Table 6.
Animal | Brain region | Helper AAV | H129-dTK-T2 | Perfusion time (Day)b | ||||
---|---|---|---|---|---|---|---|---|
AAV (1 × 1012 vg/mL) | Vol.a (μL) | Inject. time | Dose (pfu) | Vol.a (μL) | Inject. time | |||
C57BL/6 | MOB | AAV2/9-TK-GFP | 0.45 | Day 1 | 2.00 × 105 | 0.40 | Day 22 | Day 27 |
C57BL/6 | DG | AAV2/9-TK-GFP | 0.20 | Day 1 | 1.00 × 105 | 0.20 | Day 22 | Day 27 |
C57BL/6 | AuD | AAV2/9-TK-GFP | 0.20 | Day 1 | 5.00 × 104 | 0.10 | Day 22 | Day 28 |
C57BL/6 | IC | AAV2/9-TK-GFP | 0.20 | Day 1 | 5.00 × 104 | 0.10 | Day 22 | Day 27 |
aInjected volume should not exceed 0.5 μL for brain regions.
bExtending the waiting time before perfusion normally results in brighter neural labeling and more labeled post-synaptic neurons. However, the starter neurons are also more severely damaged due to H129-dTK-T2 toxicity when replication occurs.